Evidence map›Paper›PMID 37067070›Full record

ArticleHuman vaccines & immunotherapeutics2023

Temporal association between COVID-19 vaccination and Raynaud's phenomenon: A case series.

Marcus Lisy, Nikolaus Urban, Sophie Brunner-Ziegler, Benedikt Weber, Wolfgang M Bauer, Eva Dassler, Renate Koppensteiner, Alessandra Handisurya

Open access · goldAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Marcus LisyDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-2473-9841
Nikolaus UrbanDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-4052-1092
Sophie Brunner-ZieglerDivision of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Benedikt WeberDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-7217-4590
Wolfgang M BauerDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-0155-1176
Eva DasslerDivision of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Renate KoppensteinerDivision of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Alessandra HandisuryaDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-9823-7644
Medical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 vaccine-related adverse events are mostly minor to moderate, and serious events are rare. Single cases of Raynaud's phenomenon (RP) in temporal proximity to COVID-19 vaccination have been reported. Demographic data, medical history, and detailed information regarding vaccination status and RP characteristics were obtained from patients with confirmed RP after COVID-19 vaccination. Fifteen participants reported the initial manifestation of RP, which occurred in 40% after the first, in 33% after the second, and in 27% after the third vaccination. RP development and occurrence of episodes were not linked to any specific vaccine type. New onset of disease was observed in 40% of the vaccinees after BNT162b2, in 33% after mRNA-1273, and in 27% after ChAdOx1 vaccination. Three out of four participants with preexisting RP prior to COVID-19 vaccination reported aggravation in frequency and intensity after immunization. Although COVID-19 vaccination is pivotal in controlling the pandemic, the observed temporal association between vaccine administration and RP occurrence warrants global activities to support pharmacovigilance for the detection of adverse reactions, one of which may include RP.

Indexed as

COVID-19COVID-19 VaccinesRaynaud DiseaseBNT162 VaccineHumansVaccinationBNT162 VaccineCOVID-19 Vaccinesadverse effectBNT162b2 vaccineChAdOx1 vaccineCOVID-19 vaccinationCOVID-19 vaccinemRNA-1273 vaccineRaynaud’s phenomenonRaynaud’s syndrome

Identifiers

PMID37067070
PMCPMC10116941
OpenAlexW4366084217

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.